CTChengyi Tu

Chengyi Tu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chengyi Tu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Generation of Human Cardiomyocytes With Adult-Like Metabolism by a Chemically Defined Medium for Mitochondrial Disease Modeling

    by Chengyi Tu, Arianne Caudal, Yu Liu, Nadjet Belbachir, Ana Kojic, Brett Stern, Lu Ren, Erin Hu, Nathan Cunningham, Brian Yu, et al.

    BACKGROUND: Human induced pluripotent stem cell (iPSC)–derived cardiomyocytes (iPSC cardiomyocytes) as a model for cardiac disease have become increasingly important, bolstered by the Food and Drug Administration’s initiative to promote novel alternative methods for biomedical research. A key limitation of metabolically immature iPSC cardiomyocytes is their limited ability to accurately recapitulate mitochondria-dependent pathologies, such as Friedreich ataxia–associated cardiomyopathy. Adult cardiomyocytes are characterized by a high density of interfibrillar mitochondria, abundant respiratory complexes (I–V) that form supercomplexes, and efficient utilization of fatty acids to drive mitochondrial respiration. These unique metabolic structures and functions are largely missing in iPSC cardiomyocytes. Further, whether iPSC cardiomyocytes can efficiently utilize fatty acids for respiration in the presence of glucose, a unique adult feature, remains unclear. METHODS: We developed a chemically defined, 11-component maturation medium (MM11) designed using a bioinformatics-guided strategy that identified high-fidelity transcriptional markers of adult cardiac metabolic maturity. Human iPSC cardiomyocytes were treated with MM11 for 2 weeks and evaluated at the molecular, structural, and functional levels, with an emphasis on mitochondrial maturity. We benchmarked our results with isolated primary adult human cardiomyocytes. Last, we tested whether this method could enable us to more accurately model Friedreich ataxia cardiomyopathy. RESULTS: MM11 treatment increased expression of metabolic pathways, including mitochondrial respiration and fatty acid metabolism, at the transcript and protein levels. Ultrastructural analyses revealed the formation of interfibrillar mitochondria and mitochondrial respiratory supercomplexes, a feature never shown in previous reports. Functionally, MM11-treated iPSC cardiomyocytes exhibited substantially increased oxidative phosphorylation and a metabolic preference for fatty acid utilization in the presence of physiologic substrates, as determined by oxygen consumption assays and 13 C isotope tracing. CONCLUSIONS: MM11 promotes robust metabolic maturation of human iPSC cardiomyocytes, enabling sophisticated mitochondrial architecture and substrate utilization. These metabolically matured cardiomyocytes more faithfully model mitochondria-dependent cardiac pathologies, including ischemia-reperfusion injury and Friedreich ataxia cardiomyopathy, improving the use of iPSC cardiomyocytes for mechanistic studies of human heart disease.

  • Cell Village Captures Populational Heterogeneity of Sunitinib Cardiotoxicity

    by Ana Kojic, Yu Liu, Nadjet Belbachir, Chengyi Tu, Mengcheng Shen, Arianne Caudal, Thulaj Meharwade, Mehdi Belbachir, Kevin Ford, Karim Sallam, et al.

    BACKGROUND: TKIs (tyrosine kinase inhibitors) have transformed cancer therapy; however, cardiotoxicity remains a frequent adverse effect with variable susceptibility among patients. For sunitinib, a commonly prescribed TKI, the molecular programs and functional features underlying this variability are not well defined, and clinically actionable predictors of cardiotoxicity risk remain lacking. METHODS: To investigate interindividual variability in sunitinib-induced cardiotoxic responses, we implemented the Cell Village platform consisting of human induced pluripotent stem cell–derived cardiomyocytes (iPSC-CMs) from 20 healthy donors. Pooled iPSCs were differentiated into cardiomyocytes, treated with sunitinib for 72 hours, followed by harvesting for single-nucleus RNA sequencing. Donor identity was determined using single nucleotide polymorphism-based demultiplexing. Additionally, individual line-specific transcriptomic responses to sunitinib were integrated with quantitative functional phenotyping (including contractility, electrophysiology, and recovery efficacy following tocotrienol treatment) in iPSC–CMs differentiated from a subset of 10 lines. RESULTS: Sunitinib induced a robust global transcriptional response characterized by dysregulation of tyrosine kinase signaling, cytoskeletal organization, ion channels, and calcium-handling pathways. Although the pathway-level changes were shared, individual donor lines displayed heterogeneity in both gene expression patterns and functional impairment. Across functional parameters, relaxation velocity was the most consistently correlated with toxicity severity. Integration of each iPSC line’s functional data with the corresponding transcriptomic signatures identified gene modules related to calcium handling and structural organization strongly correlated with donor-specific toxicity and recovery indices. Pharmacological validation using tocotrienol demonstrated partial, donor-dependent improvement of sunitinib-related iPSC–CM impairments. CONCLUSIONS: This proof-of-concept study establishes a scalable, donor-resolved platform that links pooled transcriptomic profiling with functional toxicity and recovery phenotypes in human cardiomyocytes. By linking molecular perturbations to functional outcomes across genetically diverse backgrounds, this approach provides a framework for dissecting interindividual variability in TKI-associated cardiotoxicity. More broadly, it provides a foundation for extending population-scale cardiotoxicity assessment to additional drugs and protective interventions.


  • Open Access

    Human Induced Pluripotent Stem Cells as a Screening Platform for Drug-Induced Vascular Toxicity

    by Chengyi Tu, Nathan J. Cunningham, Mao Zhang, Joseph C. Wu

    Evaluation of potential vascular injury is an essential part of the safety study during pharmaceutical development. Vascular liability issues are important causes of drug termination during preclinical investigations. Currently, preclinical assessment of vascular toxicity primarily relies on the use of animal models. However, accumulating evidence indicates a significant discrepancy between animal toxicity and human toxicity, casting doubt on the clinical relevance of animal models for such safety studies. While the causes of this discrepancy are expected to be multifactorial, species differences are likely a key factor. Consequently, a human-based model is a desirable solution to this problem, which has been made possible by the advent of human induced pluripotent stem cells (iPSCs). In particular, recent advances in the field now allow the efficient generation of a variety of vascular cells (e.g., endothelial cells, smooth muscle cells, and pericytes) from iPSCs. Using these cells, different vascular models have been established, ranging from simple 2D cultures to highly sophisticated vascular organoids and microfluidic devices. Toxicity testing using these models can recapitulate key aspects of vascular pathology on molecular (e.g., secretion of proinflammatory cytokines), cellular (e.g., cell apoptosis), and in some cases, tissue (e.g., endothelium barrier dysfunction) levels. These encouraging data provide the rationale for continuing efforts in the exploration, optimization, and validation of the iPSC technology in vascular toxicology.